| Primary |
| Product Used For Unknown Indication |
35.0% |
| Essential Thrombocythaemia |
25.6% |
| Thrombocytosis |
10.3% |
| Thrombocythaemia |
5.1% |
| Myeloproliferative Disorder |
4.3% |
| Hypertension |
2.6% |
| Platelet Count Increased |
2.6% |
| Depression |
1.7% |
| Drug Use For Unknown Indication |
1.7% |
| Oedema |
1.7% |
| Polycythaemia Vera |
1.7% |
| Asthma |
0.9% |
| Blood Cholesterol Increased |
0.9% |
| Blood Disorder |
0.9% |
| Blood Pressure Increased |
0.9% |
| Cardiac Failure |
0.9% |
| Chronic Myelomonocytic Leukaemia |
0.9% |
| Myelofibrosis |
0.9% |
| Skin Ulcer |
0.9% |
| Thrombosis |
0.9% |
|
| Death |
9.1% |
| Pulmonary Embolism |
9.1% |
| Cerebrovascular Accident |
6.1% |
| Intentional Overdose |
6.1% |
| Left Ventricular Failure |
6.1% |
| Pancytopenia |
6.1% |
| Platelet Count Decreased |
6.1% |
| Pulmonary Hypertension |
6.1% |
| Thrombocythaemia |
6.1% |
| Vertigo |
6.1% |
| White Blood Cell Count Increased |
6.1% |
| Atrioventricular Block Complete |
3.0% |
| Bile Duct Cancer |
3.0% |
| Breast Cancer |
3.0% |
| Cardiac Failure Congestive |
3.0% |
| Cardiomyopathy |
3.0% |
| Cerebral Haemorrhage |
3.0% |
| Condition Aggravated |
3.0% |
| Drug Intolerance |
3.0% |
| Emphysema |
3.0% |
|
| Secondary |
| Product Used For Unknown Indication |
29.0% |
| Thrombocytosis |
11.3% |
| Essential Thrombocythaemia |
9.7% |
| Polycythaemia Vera |
8.1% |
| Chronic Myelomonocytic Leukaemia |
6.5% |
| Myelofibrosis |
6.5% |
| Myeloproliferative Disorder |
6.5% |
| Drug Use For Unknown Indication |
4.8% |
| Hypertension |
4.8% |
| Depression |
3.2% |
| Oedema |
3.2% |
| Pulmonary Hypertension |
3.2% |
| Arthritis |
1.6% |
| Platelet Count Increased |
1.6% |
|
| Pancytopenia |
23.5% |
| Haematemesis |
17.6% |
| Sick Sinus Syndrome |
11.8% |
| Vertigo |
11.8% |
| Cardiomyopathy |
5.9% |
| Death |
5.9% |
| Haemoptysis |
5.9% |
| Paraesthesia Oral |
5.9% |
| Platelet Count Decreased |
5.9% |
| Small Intestinal Haemorrhage |
5.9% |
|
| Concomitant |
| Osteoporosis |
27.8% |
| Systemic Lupus Erythematosus |
22.2% |
| Hypertension |
7.8% |
| Myelodysplastic Syndrome |
6.7% |
| Angiogram |
5.6% |
| Platelet Count Increased |
5.6% |
| Drug Use For Unknown Indication |
4.4% |
| Thrombocytopenia |
4.4% |
| Chronic Myeloid Leukaemia |
2.2% |
| Nuclear Magnetic Resonance Imaging |
2.2% |
| Bronchitis |
1.5% |
| Cerebrovascular Accident Prophylaxis |
1.5% |
| Essential Thrombocythaemia |
1.5% |
| Anaemia |
1.1% |
| Anxiety |
1.1% |
| Product Used For Unknown Indication |
1.1% |
| Pulmonary Arterial Hypertension |
1.1% |
| Blood Iron Increased |
0.7% |
| Crohn's Disease |
0.7% |
| Depression |
0.7% |
|
| Wound Infection Staphylococcal |
32.9% |
| Skin Tightness |
6.8% |
| Vasculitis |
6.8% |
| Fatigue |
5.5% |
| Fall |
4.1% |
| Rectal Haemorrhage |
4.1% |
| Stress Fracture |
4.1% |
| Cardiac Failure Congestive |
2.7% |
| Joint Swelling |
2.7% |
| Melaena |
2.7% |
| Oedema Peripheral |
2.7% |
| Renal Failure Chronic |
2.7% |
| Skin Ulcer |
2.7% |
| Supraventricular Tachycardia |
2.7% |
| Thrombocytopenia |
2.7% |
| Upper Respiratory Tract Infection |
2.7% |
| Urinary Tract Infection |
2.7% |
| Vomiting |
2.7% |
| Weight Increased |
2.7% |
| White Blood Cell Count Decreased |
2.7% |
|
